Oncternal Therapeutics (NASDAQ:ONCT) Given “Hold” Rating at Brookline Capital Management

Brookline Capital Management reissued their hold rating on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report report published on Thursday, Marketbeat reports.

Several other equities research analysts also recently weighed in on the stock. StockNews.com started coverage on shares of Oncternal Therapeutics in a research note on Sunday, September 8th. They set a hold rating for the company. HC Wainwright cut their price target on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating for the company in a report on Monday, August 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus price target of $20.00.

Oncternal Therapeutics Trading Down 14.1 %

NASDAQ:ONCT opened at $1.46 on Thursday. The stock has a fifty day moving average price of $5.37 and a 200 day moving average price of $7.45. Oncternal Therapeutics has a 12-month low of $1.32 and a 12-month high of $13.14. The firm has a market cap of $4.32 million, a PE ratio of -0.12 and a beta of 1.39.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its earnings results on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.03) by $0.14. The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. During the same quarter in the prior year, the company posted ($3.00) earnings per share. Equities analysts forecast that Oncternal Therapeutics will post -11.4 EPS for the current year.

Hedge Funds Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned about 0.94% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.